New oral cancer pill tested in patients who have run out of options
Disease control
Terminated
This early-stage study tested a new oral medication called IK-595 in adults with advanced solid tumors that have specific genetic changes (RAS or RAF mutations) and no remaining standard treatment options. The main goals were to find a safe dose, see how the body processes the dr…
Phase: PHASE1 • Sponsor: Ikena Oncology • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC